Roche's Obesity Drug Shows Promise But Trails GLP-1 Giants Novo Nordisk, Eli Lilly

Roche's Obesity Drug Shows Promise But Trails GLP-1 Giants Novo Nordisk, Eli Lilly - Roche Holding (OTC:RHHBY) - Benzinga

CHF351.50 ROG.SW Roche Holding AG (SIX) pre-market Mar 2026: Phase II upside - Meyka

Roche's (RHHBY) Genentech Reports Positive Trial Results for Obe - GuruFocus

Roche Holding Ag Announces Positive Phase Ii Results for Petrelintide, an Amylin Analog Developed for People Living with Overweight and Obesity - marketscreener.com

Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity

Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity

Is Roche Holding (SWX:ROG) Still Attractively Priced After Strong Three Year Share Gains? - Yahoo Finance

Respiratory Disease Testing Market Global Forecast Report 2026-2032: $9.32 Bn Opportunities in Integrating Advanced Diagnostics, Leveraging Partnerships, and Enhancing Supply Resilience

New survey demonstrates how diabetes limits day-to-day freedom for people around the world and highlights need for predictive tools

Roche Holding (SWX:ROG) Valuation Check After Positive Fenebrutinib Phase III Multiple Sclerosis Results - simplywall.st

GLP-1 Receptor Agonist Business Analysis Report 2026: Market to Reach $137.4 Billion by 2030 - Clinical Trials Exploring GLP-1 Role in NAFLD and NASH Unlock Future Opportunities

Roche (RHHBY) Targets Top Position in Weight Loss Drug Market - GuruFocus

Is Roche Holding (SWX:ROG) Offering Value After Recent Share Price Strength And DCF Indications - simplywall.st

Wolfe Maintains Outperform on Roche Holding AG (RHHBY) Feb 26, 2026 - Meyka

Roche Holding AG (OTCMKTS:RHHBY) Receives Consensus Rating of "Hold" from Analysts - MarketBeat